Albemarle (ALB) ended the recent trading session at $120.78, demonstrating a +1.1% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 1.01%. Elsewhere, the Dow saw a downswing of 0.77%, while the tech-heavy Nasdaq depreciated by 1.4%.
Shares of the specialty chemicals company witnessed a loss of 25.5% over the previous month, trailing the performance of the Basic Materials sector with its loss of 10.7%, and the S&P 500's gain of 0.32%.
Investors will be eagerly watching for the performance of Albemarle in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 5, 2026. The company's earnings per share (EPS) are projected to be $3.21, reflecting a 2818.18% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $1.52 billion, reflecting a 14.53% rise from the equivalent quarter last year.
ALB's full-year Zacks Consensus Estimates are calling for earnings of $13.06 per share and revenue of $6.13 billion. These results would represent year-over-year changes of +1753.16% and +19.15%, respectively.
Investors should also note any recent changes to analyst estimates for Albemarle. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 5.44% upward. Albemarle presently features a Zacks Rank of #2 (Buy).
From a valuation perspective, Albemarle is currently exchanging hands at a Forward P/E ratio of 9.15. This represents a discount compared to its industry average Forward P/E of 15.01.
The Chemical - Diversified industry is part of the Basic Materials sector. This group has a Zacks Industry Rank of 158, putting it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Albemarle Corporation (ALB): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).